GlassScriptPhysician profile
James J Figge
NPI 1649314899
$6,190.74
in general payments reported to CMS, 2019-2025
39 companies · $858 in 2025
The $858 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,343 · 2020: $361 · 2021: $820 · 2022: $1,277 · 2023: $1,322 · 2024: $210 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,311 · Gift: $59.40 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,311.16 |
| Gift | $59.40 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $713.83 | 2019-2025 | Mounjaro, Jardiance, Baqsimi |
| Sanofi-Aventis U.S. LLC | $474.35 | 2019-2025 | |
| Insulet Corporation | $416.37 | 2019-2025 | Omnipod |
| Novo Nordisk INC | $406.37 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Dexcom, INC. | $379.64 | 2019-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $372.13 | 2019-2025 | Jardiance |
| Abbvie INC. | $298.00 | 2019-2023 | |
| Mannkind Corporation | $282.04 | 2019-2023 | Afrezza |
| Tandem Diabetes Care, INC. | $263.05 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $252.12 | 2021-2023 | |
| Abbott Laboratories | $240.20 | 2019-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $231.10 | 2019-2022 | |
| Amgen INC. | $224.23 | 2019-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $186.04 | 2019-2022 | |
| Corcept Therapeutics | $176.95 | 2021-2023 | Korlym |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $158.25 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Merck Sharp & Dohme LLC | $153.32 | 2019-2023 | Steglatro, Steglujan |
| Ibsa Pharma INC. | $131.75 | 2019-2023 | Tirosint, Licart |
| Xeris Pharmaceuticals, INC. | $86.32 | 2021-2023 | Keveyis |
| Medtronic, INC. | $82.12 | 2024-2025 | Minimed 780g |
| Amneal Pharmaceuticals LLC | $77.17 | 2021-2023 | Unithroid |
| Radius Health, INC. | $70.00 | 2019-2023 | |
| Recordati_rare_diseases_inc. | $65.10 | 2021-2023 | Isturisa, Signifor Lar |
| Ultragenyx Pharmaceutical INC. | $50.94 | 2021-2022 | |
| Renalytix Ai, INC. | $50.57 | 2022-2023 | Kidneyintelx Blood Collection Convenience Kit |
| Amarin Pharma, INC. | $47.61 | 2019-2020 | |
| Sequel Med Tech, LLC | $39.51 | 2025 | Twiist |
| Embecta Corp. | $35.07 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Shire North American Group INC | $29.04 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.79 | 2019 | |
| Opko Pharmaceuticals, LLC | $24.90 | 2020 | |
| Horizon Therapeutics Plc | $24.76 | 2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $24.53 | 2025 | Yorvipath |
| Eusa Pharma (US) LLC | $20.06 | 2022 | |
| Ascensia Diabetes Care US INC. | $19.88 | 2023 | |
| Lifescan, INC. | $16.97 | 2019 | |
| Halozyme INC | $14.84 | 2023 | |
| Intuity Medical INC | $13.27 | 2022 | |
| Pfizer INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Figge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.